A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
NCT ID: NCT05059223
Last Updated: 2025-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
90 participants
INTERVENTIONAL
2021-09-15
2024-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
NCT01681121
A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness
NCT01485770
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
NCT04072380
"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"
NCT02348632
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AXS-12 (reboxetine)
Up to 5 weeks
AXS-12 (reboxetine)
AXS-12 tablets, taken twice daily
Placebo
Up to 5 weeks
Placebo
Placebo tablets, taken twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AXS-12 (reboxetine)
AXS-12 tablets, taken twice daily
Placebo
Placebo tablets, taken twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary diagnosis of narcolepsy with cataplexy
* Willing and able to comply with the study requirements
Exclusion Criteria
* Clinically significant psychiatric disorders
15 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Axsome Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Site
Alabaster, Alabama, United States
Clinical Research Site
Peoria, Arizona, United States
Clinical Research Site
Phoenix, Arizona, United States
Clinical Research Site
Redwood City, California, United States
Clinical Research Site
San Diego, California, United States
Clinical Research Site
Santa Ana, California, United States
Clinical Research Site
Santa Monica, California, United States
Clinical Research Site
Boulder, Colorado, United States
Clinical Research Site
Colorado Springs, Colorado, United States
Clinical Research Site
Brandon, Florida, United States
Clinical Research Site
Clearwater, Florida, United States
Clinical Research Site
Doral, Florida, United States
Clinical Research Site
Kissimmee, Florida, United States
Clinical Research Site
Miami, Florida, United States
Clinical Research Site
Miami Lakes, Florida, United States
Clinical Research Site
St. Petersburg, Florida, United States
Clinical Research Site
Tampa, Florida, United States
Clinical Research Site
Winter Park, Florida, United States
Clinical Research Site
Atlanta, Georgia, United States
Clinical Research Site
Atlanta, Georgia, United States
Clinical Research Site
Gainesville, Georgia, United States
Clinical Research Site
Macon, Georgia, United States
Clinical Research Site
Stockbridge, Georgia, United States
Clinical Research Site
Honolulu, Hawaii, United States
Clinical Research Site
Peoria, Illinois, United States
Clinical Research Site
Fort Wayne, Indiana, United States
Clinical Research Site
Chevy Chase, Maryland, United States
Clinical Research Site
Newton, Massachusetts, United States
Clinical Research Site
North Dartmouth, Massachusetts, United States
Clinical Research Site
Kalamazoo, Michigan, United States
Clinical Research Site
Novi, Michigan, United States
Clinical Research Site
Maplewood, Missouri, United States
Clinical Research Site
Las Vegas, Nevada, United States
Clinical Research Site
West Long Branch, New Jersey, United States
Clinical Research Site
Brooklyn, New York, United States
Clinical Research Site
New Hyde Park, New York, United States
Clinical Research Site
Denver, North Carolina, United States
Clinical Research Site
Gastonia, North Carolina, United States
Clinical Research Site
Huntersville, North Carolina, United States
Clinical Research Site
Cincinnati, Ohio, United States
Clinical Research Site
Wyomissing, Pennsylvania, United States
Clinical Research Site
Charleston, South Carolina, United States
Clinical Research Site
Columbia, South Carolina, United States
Clinical Research Site
Austin, Texas, United States
Clinical Research Site
San Antonio, Texas, United States
Clinical Research Site
Sugar Land, Texas, United States
Clinical Research Site
Williamsburg, Virginia, United States
Clinical Research Site
Markham, Ontario, Canada
Clinical Research Site
Toronto, Ontario, Canada
Clinical Research Site
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
SYMPHONY Study Website
Axsome Therapeutics Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AXS-12-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.